Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Plant compound kills brain tumor cells

30.08.2002


A chemical isolated from a weed that grows in mountain meadows in the western United States kills the cells of an aggressive brain cancer that affects some children. The compound, cyclopamine, blocks a signaling pathway that appears to be important for the survival of medulloblastoma, a form of cancer for which there is no effective treatment.

In an article published in the August 30, 2002, issue of the journal Science, a research team led by Howard Hughes Medical Institute investigator Philip A. Beachy reported that cyclopamine effectively killed cultured mouse medulloblastoma cells and tumors implanted in animals, as well as medulloblastoma cells extracted from human tumors.

“It will be difficult to obtain sufficient quantities of cyclopamine, since it must be extracted and purified from the plant source, Veratrum californicum, the corn lily,” said Beachy, who is at The Johns Hopkins University School of Medicine. “However, we believe that with this study, the evidence is in place to justify an effort to develop a supply so that it can be tested in humans.” Beachy and his colleagues at Johns Hopkins collaborated with researchers from the Fred Hutchinson Cancer Research Center and the University of Washington/Children’s Hospital in Seattle.



Beachy said there are some parallels between cyclopamine and taxol, a drug used to treat breast cancer drug that was initially in short supply because it had to be isolated from the bark of the Pacific yew tree. However, as taxol proved clinically effective, researchers developed an alternate method of partial synthesis of the compound from a more plentiful precursor in the needles that made the drug available in sufficient supply.

Beachy and his colleagues began to explore whether cyclopamine would be effective against medulloblastoma after studies by several groups, including HHMI investigator Matthew Scott and his colleagues at Stanford University, showed that both animals and humans developed tumors, including medulloblastomas, when the Hedgehog signaling pathway was activated. The pathway — named for its key regulatory protein Hedgehog — has long been known to be critical for the growth and differentiation of cells during embryonic development. Scott and his colleagues showed that the tumors they studied consisted of cells that had most likely reverted to a highly proliferative embryonic state, due to a mutation that enabled the activation of the Hedgehog pathway.

The earlier studies showed that the Hedgehog pathway was switched on when the function of one of the pathway’s key genes, called Patched, was lost because of mutation. The protein produced by Patched normally represses a downstream member of the Hedgehog pathway — a protein called Smoothened. Loss of Patched activates the Smoothened protein, turning on the Hedgehog pathway and leading to malignancy.

Beachy and his colleagues had shown previously that cyclopamine blocks the Hedgehog pathway in mouse embryos by inhibiting the activity of Smoothened. Reasoning that the drug might also prevent activation of the Hedgehog pathway in tumors, the scientists tested cyclopamine’s effects on a mouse model developed in Scott’s laboratory, in which one copy of the Patched gene had been disrupted. In these mice, Beachy and his colleagues also removed the gene for p53, a protein that normally triggers the death of cells with damaging mutations. The mice developed medulloblastomas at a young age when expression of the second normal Patched gene was inactivated.

The researchers cultured medulloblastoma cells from the mice and introduced those tumor cells into other mice that had compromised immune systems. “We showed that in these tumor cells we could readily suppress the Hedgehog pathway by treating the tumors with cyclopamine,” said Beachy. “We next decided to see whether the drug would affect tumors that had already been established in mice by injecting the tumor cells. We were pleased to see that cyclopamine could not only block the Hedgehog pathway, but could also stop the growth of these tumors and even cause them to regress,” he said.

The next logical step, said Beachy, was to determine whether cyclopamine was effective in human medulloblastomas. For these studies, co-author James Olson and colleagues at the Fred Hutchinson Cancer Research Center supplied medulloblastoma cells from patients who had undergone surgery to remove the tumors.

“When we treated dispersed cells from these tumors with cyclopamine, they died very quickly, and in fact, the drug appeared to be killing the cells faster than any drug Jim Olson and his colleagues had yet tested,” said Beachy. Also promising, said Beachy, was that in the animal studies, the drug produced no discernible side effects. “Of course, we can’t be sure that there are no side effects at this point, since we can’t ask a mouse how it’s feeling,” said Beachy. “But we saw no obvious adverse effects from the treatment.”

One promising result from the studies of human tumor cells, said Beachy, was that all seven of the human medulloblastomas the scientists tested responded dramatically to cyclopamine. “Genetic studies have shown that only perhaps twenty percent of such sporadic tumors can be assigned to mutations that specifically activate the Hedgehog pathway,” he said. “So, this finding suggests that perhaps activation of the Hedgehog pathway is essential to tumorigenesis, even when it is not specifically switched on by mutation.”

Although Beachy advocates immediate pre-clinical and clinical trials of cyclopamine for medulloblastoma, he cautioned that supply is a critical problem. “Right now, cyclopamine must be purified from the corn lily, and it is unclear how much could be harvested or cultivated,” said Beachy. “Synthesizing cyclopamine might be possible, but it would be very difficult.”

Jim Keeley | EurekAlert!

More articles from Health and Medicine:

nachricht Electrical 'switch' in brain's capillary network monitors activity and controls blood flow
27.03.2017 | Larner College of Medicine at the University of Vermont

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Northern oceans pumped CO2 into the atmosphere

27.03.2017 | Earth Sciences

Fingerprint' technique spots frog populations at risk from pollution

27.03.2017 | Life Sciences

Big data approach to predict protein structure

27.03.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>